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Abstract 
The efficacy of cancer immunotherapy relies on the ability of the host immune system to recognise 
the cancer as non-self and eliminate it from the body. Whilst this is an extremely fertile area of 
medical research, with positive clinical trials showing durable responses, attention must be paid to 
the subset of patients that do not respond to these treatments. Immune surveillance and 
immunoediting by the host could itself select for immune-evasive tumour cells during tumour 
development leading to immunotherapy resistance.  One such mechanism of non-efficacy or 
resistance is the epigenetic silencing of a specific gene required in the immunotherapy response 
pathway. Epigenetics is the study of the control of expression patterns in a cell via mechanisms not 
involving a change in DNA sequence. All tumour types show aberrant epigenetic regulation of genes 
involved in all the hallmarks of cancer, including immunomodulation. Inhibition of key enzymes 
involved in maintenance of epigenetic states is another important area of research for new 
treatment strategies for cancer.  Could epigenetic therapies be used to successfully enhance the 
action of immunomodulatory agents in cancer, and are they acting in the way we imagine? An 
understanding of the effects of epigenetic therapies on immunological pathways in both the tumour 
and host cells, especially the tumour microenvironment, will be essential to further develop such 
combination approaches. 
Cancer immunotherapy 
Attitudes towards cancer immunotherapy have fluctuated dramatically over time. The history of 
attempting to harness the body’s own arsenal to reverse the uncontrollable cell proliferation 
inherent in cancer  dates back to the 1800s, when Coley’s toxin [1, 2] was first used in an attempt to 
provoke an immune response that simultaneously targeted the neoplastic growth, with varying 
degrees of success.  However, the ascent of radiotherapy and chemotherapy, as well as the advent 
of genomics, leading to the popular view of cancer as a disease of the genome, has led to reduced 
priority of immunotherapeutic cancer treatments. In the last two decades however, there has been 
an explosion of immunotherapy successfully modulating the progress of cancer, from the FDA 
approval of multiple monoclonal antibodies used in a plethora of malignancies [3] to the 
development of adoptive T cell strategies, an example of the “personalised medicine” approach [4]. 
This was underscored by the addition of evasion of immune response to the hallmarks of cancer [5]. 
To understand how tumours evade the immune system, we must first understand how the immune 
system targets and kills precancerous cells in the process of immune surveillance. Both the innate 
and adaptive immune responses play important roles in the recognition of malignant cells [6]. 
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Engineered mouse models lacking various components of the immune system have been shown to 
readily develop tumours when compared to their immunocompetent counterparts (reviewed in [7]), 
emphasising the importance of each part of the immune system.  
The presence of Tumour Associated Macrophages (TAMs) within the tumour microenvironment has 
largely been seen as a pro-tumourogenic mechanism. They appear to activate and maintain the 
chronic inflammation process, enhancing invasion, angiogenesis and cancer cell proliferation [8]. 
However, as part of the innate immune system, macrophages have been shown to exist in two 
polarised states, with the M1 state acting to attract and activate CD4+ T helper cells, and therefore 
activate adaptive immune pathways [9]. The observed TAMs appear to be more like the M2 
polarisation, linked with immune suppressive mechanisms, such as recruitment of CD4+ CD25+ 
regulator T cells (Tregs) which function to deactivate cytotoxic T cells [10].  
Neutrophils are the most abundant white blood cell and part of the innate immune system. Their 
identification as Tumour Associated Neutrophils (TANs) highlights their pro-tumourogenic abilities, 
for example the production of reactive oxygen species (ROS), which can lead to DNA damage and 
mutation [11, 12]. However, they have also been shown to mirror the plasticity of macrophages and 
form an anti-tumourogenic state, with immunostimulatory characteristics and cancer cell specific 
cytotoxic action [13]. 
The main mechanism of tumour cell killing is via CD8+ cytotoxic T-cells. These cells recognise 
antigens presented by the major histocompatibility complex (MHC) I from affected cells. The T cell 
receptor specifically recognises and binds to the presented antigen. For the T cell to be activated, a 
second signal is required, for examples the antigenic independent co-stimulatory interaction of CD28 
on the T cell with B7 on an antigen presenting cell (APC) resulting in increased T cell expansion, 
production of cytokines and downstream effects thereof. In the absence of a second signal, T cells 
are not efficiently activated in response to that antigen [14]. 
There are two key T cell receptors that negatively regulate T cell activation, CTLA4 (cytotoxic T-
lymphocyte associated antigen -4) and PD-1 (Programmed cell Death molecule 1). CTLA4 is 
upregulated on T cells after activation and competes for the ligand of the stimulatory T cell surface 
receptor CD28, B7, and causes T cell arrest [15]. PD-1 interacts with ligands PD-L1 and PD-L2 and 
inhibits T cell activation by blocking kinase activity [16]. Their natural function is as a checkpoint, to 
control the activation of T cells to ensure that the immune response is appropriate and avoids 
overactivation against healthy cells [17].  
Tumours can evade these immune mechanisms in a number of ways. The secretion of cytokines such 
as interleukins (IL) -6, -8, -10, and TGF-β from tumours has been shown to affect the activation of T 
cells and macrophages, and reduce successful immunesurveillance by supressing inflammation [18]. 
Upregulation of the checkpoint receptor ligands has been observed, allowing the deactivation of the 
cytotoxic T cell response [19]. Downregulation of key proteins in the process of antigen 
presentation, as well as the expression of tumour associated antigens (TAAs) or cancer germline 
antigens (CGAs) themselves has been shown to assist immune evasion [20]. Overall the immune 
system has become more tolerant to tumour self-antigens, and the main challenge in effective 
immunology is overcoming this tolerance.    
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Multiple approaches have been developed in an attempt to overcome this acquired tolerance. 
Systemic administration of cytokines such as IFNα and IL2 have had some success, activating the 
immune system in a non-specific manner [21]. However this non-specificity can lead to toxicity 
associated side-affects and or simultaneous activation of the repressive Tregs, making it hard to 
predict the outcome of this therapy [22]. Another approach is to collect T cells from a patient,  
stimulate them ex vivo  with a specific antigen and the appropriate cytokines to stimulate them, 
before transferring them back into the patient, in a process known as adoptive T cell therapy [23]. 
These activated T cells should be primed for activity against the specific tumour antigens of that 
particular patient, and mediate a successful immune response on the cancer. However it has been 
found that only 30-40% of biopsies contain enough T cells within their population for successful 
expansion, and the process is labour intensive and can take up to 6 weeks [24].  
A recent breakthrough in cancer immunotherapy is the use of monoclonal antibodies against the 
immune checkpoints CTLA4 and PD-1. As described earlier, the activation of these receptors by their 
ligands leads to inactivation or death of the associated T cell, reducing the immune response. Some 
cancers have been shown to have an overexpression of ligands, enhancing their immune evasion. In 
the case of ovarian cancer, it was discovered that PD-L1, the ligand for PD-1, was overexpressed on 
the cell surface, and this overexpression was associated with poor prognosis [25]. Blocking these 
receptors with monoclonal antibodies inhibits the inactivation, maintaining an activated cytotoxic T 
cell state against the tumour [3].  
A number of these checkpoint inhibitors have been FDA approved for use in advanced and 
metastasised non-small cell lung cancer and melanoma [26], and since 2012, a number of these have 
been awarded FDA Breakthrough Therapy designation, a status which is designed to expedite the 
development and review of medicines with impressive preclinical data indicating that the drug may 
demonstrate substantial improvement over existing therapies [27]. In the first phase III study of 
Ipilimumab, a CTLA4 blocking antibody, in metastatic melanoma, the survival rate at 2 years was 
18%, compared with 5% in the control group [28]. A recent pooled analysis of 1861 patients from 
phase II and III trials confirmed the durability of response to Ipilimumab, finding 20% of patients 
achieving 3 years survival after treatment [29]. In non-small-cell lung cancer, an improved 
progression-free survival was observed in a phase II trial for Ipilimumab treatment in combination 
with carboplatin and paclitaxel [30] and a phase Ib trial in pancreatic cancer showed some promise 
in combination with a cancer vaccine approach (GVAX, allogeneic pancreatic tumour cells 
transfected with granulocyte macrophage colony stimulating factor (GM-CSF) gene) [31]. 
Tremelimumab, another CTLA4 blocking antibody, had some success in a single arm phase II trial of 
mesothelioma, with a proportion of patients exhibiting disease control and durable partial response 
[32]. Antibodies targeting PD-1 and PD-L1 have also shown highly durable response rates in large 
phase I studies [33-35] and continue to impress in phase III randomised trials; a trial testing 
nivolumab (anti-PD-1) against dacarbazine chemotherapy for advanced melanoma was stopped 
early due to the improved overall survival observed in the patients receiving nivolumab [36]. 
Another anti-PD-1 therapy, pembrolizumab has also shown impressive tumour response rates for 
patients with melanoma previously treated with ipilimumab [37].  
Observations of initial disease progression followed by disease response in early CTLA4 trials [38] has 
led to the proposal of alternative response criteria, known as immuned-related response criteria 
(irRC) [39]. As opposed to standard radiographic response criteria such as RECIST, irRC includes new 
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lesions to be included in total disease burden estimation and requires confirmation on a subsequent 
scan to define it as progressive disease. This measure was found to correlate better with overall 
survival [40].  
Epigenetics of cancer 
There are many definitions for epigenetics, but it can be broadly defined as the study of changes in 
organisms and tissues caused by modification of gene expression rather than alteration of the 
genetic code. It can be used to describe the transmission of heritable gene expression patterns 
through cell division [41]. The study of epigenetics encompasses several different mechanisms. DNA 
methylation is the addition of a methyl group to the 5th carbon of a cytosine residue in a CpG 
context, and is a stable mark with heritable mechanisms during cell division. The genome is mostly 
CpG-poor, depleted due to spontaneous deamination of methylated cytosines, and most of those 
cytosines that remain in these sparse regions are methylated [42]. However, regions exist that 
appear to have conserved a normal density of CpGs, and these regions tend to remain 
unmethylated, and found in promoter regions. These regions are known as CpG islands [43]. 
Methylation within a CpG island promoter can be associated with gene silencing, whereas 
methylation within the body of the gene (known as intragenic methylation, reviewed in [44]) is 
associated with higher expression of that gene. DNA methylation is thought to facilitate repression 
of transcription by preventing binding of transcription factors and therefore inhibiting the 
recruitment of DNA polymerases, or by recruiting histone modifiers with methyl binding domains 
and creating a repressive environment through another mechanism of epigenetic control, 
postranslational histone modifications [45, 46]. Such histone modifications, such as methylation, 
acetylation, and phosphorylation, are found on specific residues of the N terminal tails of histones, 
which are thought to change chromatin states. In combination, DNA methylation and histone 
modifications are thought to control accessibility to DNA and govern gene expression. A less well 
studied mechanism but by no means an unimportant one is the emerging role of miRNAs, which 
fine-tune gene expression post-transcriptionally. A host of proteins are required for the control of 
these mechanisms. DNA methyltransferases exist for both de novo generation (DNMT3a and 3b) and 
maintenance (DNMT1) of DNA methylation patterns across the genome, and the discovery of ten-
eleven translocation (TET) proteins and their role in iterative oxidation of 5-methyl-cytosine to 
hydroxyl-, formyl-, and carboxyl- forms of methyl-cytosine have pointed towards a mechanism for 
active demethylation [47, 48]. Histone modifications are controlled by the reciprocal action of 
enzyme pairs for each modification, with multiple examples of each type; histone 
methyltransferases (HMTs) and histone demethylases (HDMs) control methylation on lysine and 
arginine, histone acetyl transferases (HATs) and histone deacetylases (HDACs) control acetylation of 
lysine residues, whilst kinases and phosphorylases control the phosphorylation at serine residues.  
In the context of cancer, epigenetic regulation has been known to be disrupted for over two 
decades. Widespread hypomethylation was first reported in human cancer samples compared to 
normal samples in 1983 [49-51], and localised hypermethylation has been established to be 
associated with transcriptional repression in several tumour suppressor genes; VHL in renal cancer 
[52], MLH1 in colorectal, endometrial and gastric cancer [53], and RASSF1A in a multitude of cancers 
[54] are but a few examples of this phenomenon. The implication of localised hyper methylation and 
the associated decrease in expression of tumour suppressor genes is clear; loss of expression leads 
to loss of control of the cell and the acquisition of cancer characteristics. However genome-wide 
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hypomethylation has very different consequences that are not yet fully understood. DNA 
methylation has been proposed to contribute to the stability and integrity of the genome, and has a 
role in protecting against erroneous expression of transposable elements (TEs) and endogenous 
retroviruses (ERVs) [55]. Loss of this methylation contributes to erroneous expression of these 
silenced regions, potentially modify the expression of the genes within which these elements are 
found, as well as global changes in transcription factor levels [56]. It can also lead to aberrant 
expression of oncogenes, loss of imprinting and chromosomal instability [57]. Alongside this 
dysregulation of DNA methylation, the enzymes that control this process are also shown to be 
dysregulated, not only at the level of mRNA expression, but also with changes in protein half-life and 
stability [58] or mutation [59]. 5-hydroxymethylated cytosine is decreased in cancer [60] which is 
thought to occur through mutation of the proteins themselves, most often in haematological 
malignancies [61] or downregulation of the TET genes expression [60, 62].  
Variation of epigenetic modulators is a common alteration in malignancies. For example, the 
overexpression of EZH2, the core catalytic protein the histone methyltransferase PRC2 responsible 
for the silencing tri-methylation mark on lysine 27 of histone3, has been observed. This is caused by 
increased copy number or downregulation of associated regulatory microRNAs, as well as a 
mutation which enhances the ability of EZH2 to perform di- and tri-methylation of H3K27, and is 
found in a wide range of cancers [63, 64]. Another example is over expression of HDACs, the 
enzymes catalysing the removal of acetyl groups and creating a repressive environment to silence 
genes. The overexpression of HDACs has been observed in many cancers, [65-72], and the success of 
drugs such as vorinostat and romidepsin, (HDAC inhibitors used in the treatment of cutaneous T cell 
lymphoma [73]) emphasises the role of HDACs in cancer progression. Although the anticancer 
effects of these HDAC inhibitors are thought to be at least in part due to the accumulation of histone 
acetylation, the full mechanism is complex and may also include effects to transcription factor 
acetylation and other non-histone proteins [74-76]. 
The use of DNA hypomethylating agents azacytadine and decitabine are approved in several forms 
of myelodysplastic syndromes (MDS), chronic myelomonocytic leukemia (CMML) and acute myeloid 
leukemia (AML). Zebularine is another DNA methylation inhibitor which is not approved for use, and 
appears to have limited bioavailability [77]. These compounds are cytosine analogues, which require 
metabolic activation into the tri-phosphorylated version before they can be incorporated into the 
DNA. These cytosine analogues are recognised by DNMTs as substrates, and initiated by the 
formation of a covalent bond to the carbon 6 position. Usually this bond is then resolved upon 
methylation of the carbon 5 position, however in decitabine and azacitadine, this carbon is replaced 
by a nitrogen, preventing this reaction from taking place, trapping the enzyme in place and inhibiting 
the methylation action, as well as depleting soluble levels of DNMTs [78, 79]. This leads to 
degradation of the enzyme over time. However, the formation of these DNA-protein crosslinks has 
also been shown to initiate DNA damage response [80], indicating the anticancer mechanism of this 
type of drug is not yet fully elucidated and could encompass multiple modes. SGI-110 is a recent 
addition to the cytosine analogue family, and has been shown to have less toxicity than azacitadine 
when used in an in vivo xenograpft model of bladder cancer [81]. Non-nucleoside inhibitors are also 
being explored, such as S-adenosylhomocysteine (SAM) hydrolase inhibitor 3-Deazaneplanocin A 
(DZNep), found initially to reduce the activity of EZH2 [82]. As it acts by inhibiting the synthesis of 
SAM, the main substrate required for any methylation, it will also inhibit the methylation of DNA 
[83].  
6 
 
Over-simplification of epigenetics is rife because it is tempting to make broad generalisations about 
the action of these marks. Methylation within a CpG promoter is usually associated with silencing of 
that gene; however not all gene promoters contain CpG islands, and not all those CpG islands are 
modified in this way. Recent work that assessed TCGA cancer DNA methylation and matched 
expression found that for only a subset of the CpG island associated genes was there a significant 
correlation between a change in DNA methylation and a change in expression; indeed, cancer 
specific methylation did not appear to repress gene expression and was instead found at genes with 
existing low expression in normal tissues [84]. The direction of action is also difficult to ascertain; do 
we cause DNA methylation changes which change gene expression, or does a change in gene 
expression, potentially occurring via a different mechanism, modulate the DNA methylation 
patterns?  
Epigenetic enhancement of immunotherapy 
The theory behind using epigenetic therapeutics to enhance immunotherapy relies on the 
observation that modulating epigenetics could create a more immunogenic phenotype in a 
previously immune-evasive tumour cell, by upregulating the expression of tumour associated 
antigens or other activating ligands on the surface of the cell, or reversing silencing of the processing 
and presentation machinery required for immune activation [85, 86]. Multiple trials are underway 
assessing the combination of epigenetic and immunomodulatory therapies (Table 1). It has been 
demonstrated that treatment with the DNA demethylating agent azacitadine resulted in 
upregulation of immunomodulatory pathways in breast, colorectal and ovarian cancer cell lines [87]. 
Furthermore, it has been observed that PD-L1 expression was upregulated upon treatment with 
HDAC inhibitors in mouse and human melanoma cell lines. This resulted in a better response to PD-1 
blocking antibody therapy in mice [88]. A similar effect was also observed in non-small-cell lung 
cancer cell lines treated with azacytadine [89]. An important factor to consider in such studies is to 
ensure that the improved response to PD-1 blocking antibody is observed in an immunocompetent 
environment, as the initial PD-L1 upregulation could lead to further immune evasion by inactivating 
T cells. This indicates that the balance between the two treatments will need to be considered 
carefully. Additionally, the observation that increasing expression of PD-L1 results in a better 
response to the blocking antibody is perplexing; if the role of the blocking antibody is to inhibit this 
interaction, then the outcome should be the same if the interaction cannot exist due to low 
expression of ligand. An alternative mechanism could be responsible through the upregulation of 
other immune-modulating components. 
The re-expression of silenced cytokines in a tumour cell is another possible mechanism for the 
augmentation of immune response. A recent study found that by inhibiting both EZH2 and DNA 
methylation using DZNep and decitabine, previously silenced T helper 1-type cytokines CXCL9 and 
CXCL10 could be re-expressed, which increased T cell tumour infiltration, and slowed tumour growth 
in a mouse model of ovarian cancer.  Additionally use of DZnep and decitabine in conjunction with 
other immunotherapeutic treatments in mice, such as PD-L1 blocking therapy and adoptive T cell 
treatment, resulted in improved therapeutic efficacy [90]. Re-activating an immune-suppressive 
environment appears to have wide-reaching consequences on the system as a whole.    
The use of these epigenetic modulators is not gene specific; the effect of demethylation will happen 
across the genome. The prospect of this is perhaps counterintuitive, when we consider the 
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observation that widespread hypomethylation in cancer demonstrates that huge regions of the 
genome in these tumours have already been demethylated, yet still the tumour is immune 
repressive, begging the question as to how further demethylation can be effective. Localised 
hypermethylation in cancer has always focussed on tumour suppressor gene promoters, therefore 
the mechanism of action of epigenetic modulators is, perhaps erroneously, almost completely 
attributed to action in those regions. As previously mentioned however, DNA methylation has a role 
to play in protecting the healthy cell against unwanted expression of transposable elements and 
endogenous retroviruses [55].  It has recently been shown that the re-expression endogenous 
retroviral elements can be elicited by demethylating agents to stimulate an immune response  in 
colorectal [91] and ovarian [92] cancer, turning this particular epigenetic survival mechanism against 
the tumour cell, exposing it to immune attack, and revealing that a reliance on existing immune 
pathways may be implicit in the epigenetic drug response. Other existing epigenetic treatments have 
been shown to at least partially rely on the immune system for their anticancer mechanism; it has 
been shown that vorinostat and panobinostat require an intact immune system to effectively kill 
cancer cells in mouse models of colon cancer and leukemia/lymphoma, and this effect was 
enhanced by the addition of an IFN-γ inducing agent [93].  
An additional possible explanation for observed increased immunogenicity is a concept known as 
immunogenic cell death, a process by which the drug induced cell death causes the release of 
danger associated signals that “label” the tumour cells as pathogenic, leading to increased 
presentation of tumour antigens by the antigen processing cells (APCs), leading to induction of 
cytotoxic T cell response [94]. The cause of the cell death could be due to re-expression of previously 
epigenetically silenced genes, but also could be due to general cell toxicity associated with the drug, 
or cell death due to a different mechanism of action, for example DNA damage. HDAC inhibitors 
such as vorinostat have been observed to have this effect by improving dentric phagocytosis of brain 
tumour cell lines in vitro via the release of immunogenic cell death mediators [95].  
The consequence of epigenetic modulation can not only be viewed from the perspective of the 
cancer cell; these therapies act systemically and will have activity in all cells of the body, including 
components of the immune system itself. Due to the highly adaptive and complex nature of immune 
response, the effects could be unexpected. Epigenetics plays a role in the differentiation of a naïve T 
helper cell into either a mature type 1 or type 2 T helper through the modulation of a restrictive 
chromatin environment of the effector cytokine genes (for example, IL4) in the naïve helper T cell, to 
a poised state in newly activated progenitor T cells, before final permissive patterns of transcription 
are fixed in the mature T helper cells  [96]. There is also evidence that during V(D)J recombination in 
both T and B cell receptor generation the modulation of accessibility by epigenetic mechanisms is 
crucial, with specific chromatin structures determining the targeting of the recombinase activity 
[97]. Treatment with epigenetic modulators could therefore disrupt these important immune 
regulatory processes, and affect the immune system in ways that are not conducive to tumour cell 
killing. 
One potential aspect that the full consequences for are not yet known pertains to regulatory T cells 
(Tregs). Tregs are CD4+ CD25+ and express the transcription factor Foxp3. Tregs tend to be involved in 
reducing the immune response or T cell anergy, and are essential for the prevention of 
autoimmunity. This is achieved by deactivation of cytotoxic T cells. Despite their pivotal role in the 
inhibition of autoimmunity, it has been shown that the presence of a higher proportion of regulatory 
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T cells is associated with poorer survival in cancer [98, 99]. The transcription factor Foxp3 is one of 
the defining features of Tregs, and directs a specific gene expression pattern for this cell fate [100]. It 
has been postulated that a DNA region specifically demethylated only in Tregs is linked with 
expression of this gene, and it has been shown that demethylation of this region in non-regulatory T 
cells induces expression of Foxp3, activating the regulatory T cell gene program [101]. There is 
therefore potential for DNMT inhibitors to generate stable and specific Tregs; desirable in 
autoimmune disease, but this outcome in cancer may not be quite so advantageous, generating 
Tregs which will further repress the immune response in the tumour microenvironment.  
Work so far has focussed on examples where epigenetic modulation has enhanced immune 
response, however some studies have shown a mixed response to epigenetic treatments. For 
example, zebularine, via the upregulation of IDO, has also been shown to decrease immunogenicity, 
but only at high doses; at low doses, the immunogenicity is increased [102]. The balance between 
activated and repressing immunological response appears to be both cell and agent specific, as 
HDAC inhibition has been shown to both increase expression of tumour associated antigens, for 
example gp100 in murine melanoma cells [103], and in other systems to downregulate tumour 
antigens, for example Muc1 in mesothelioma cells [104]. This highlights the complex nature of 
epigenetic modulation, and the likelihood that it will not work as expected in all cancers or all 
individuals.  
Dysregulation of the epigenetics in immune cells may have occurred concurrently with those 
affecting cancer cells, especially if a more systemic modulation is at play, or a change in immune 
surveillance has allowed the cancer to proliferate. Methylation changes in blood have been found 
associated with cancer development in the peripheral lymphocytes of patients, for example p53 
promoter methylation in lung cancer [105, 106] or associated with other cancer risk factors, such as 
smoking [107]. Primarily used as biomarkers for diagnosis or prognosis, do these changes in 
peripheral lymphocyte DNA methylation indicate a change of function or expression profile in 
immune cells, or perhaps a change in cell type proportion? Perhaps the generation of a less 
competent immune response is required for a carcinogenic microenvironment, allowing neoplastic 
growth. Interrogation of prospective biomarkers may reveal immune modulatory programmes of 
change. If these epigenetic changes are functional, then the reversal of their states will be beneficial 
to cancer treatment. For example, expression of key activating receptors on the surface of immune 
cells, such as Fas, has been shown to be downregulated and exhibited corresponding epigenetic 
marks in a mouse model, which could be reversed by inhibiting DNA methylation [108]. In these and 
other ways, treatment with epigenetic modulating therapies may induce more competent host 
immune responses. 
Concluding remarks 
Epigenetic modulating therapies is a promising avenue with which we may successfully enhance 
immunotherapies, but the use of these drugs will not always be as straightforward as one might 
hope. Combining the complexities of immune system development and activation, with the equally 
complex actions of epigenetic mechanisms in both normal and cancerous cells, creates an intricate 
environment within which a therapeutic balance must be found (Figure 1). As the importance of the 
tumour microenvironment becomes clearer, continued research to understand this balancing act 
will be required. In vitro studies provide the background knowledge to pursue the clinical relevance 
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of these potential treatments, and care must be taken in the observation of patients for adverse side 
effects or unexpected outcomes.  
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Figure 1: Modulating epigenetics in an interconnected, dynamic system. Epigenetic modifying drugs 
impact not only tumour cells but also immune response mechanisms. The effect could be positive or 
negative. These mechanisms include A) increased secretion of chemokines, B) increased expression 
of cell surface ligands, for example PD-L1, C) expression of endogenous retroviral elements (ERVs), 
D) increased expression of processing and presentation machinery such as MHC class I, E) 
modulation of tumour associated antigens (TAAs) expression, F) change in expression of cytokines 
affecting T cell differentiation, G) induction of Treg production due to increased expression of Foxp3, 
H) changes in epigenetic mechanisms involved in V(D)J recombination during production of 
antibodies and cell surface receptors. Green components indicate where epigenetic treatment has a 
positive, anti-tumour effect in combination with immunomodulatory therapies, components in red 
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show potential negative outcomes of combination therapies, and blue components indicate systems 
where epigenetic modulation could affect function of immune pathways, but the outcome is 
unknown.  
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ClinicalTrials.gov 
Identifier 
Date Title 
Recruitment 
status 
Epigenetic 
Drug 
Immunotherapy 
Other 
Drugs 
Cancer 
NCT02546986 
First received: August 
20, 2015 
A Phase 2 Multicenter, 
Randomized, Placebo 
Controlled, Double Blind 
Study to Assess the 
Safety and Efficacy of 
CC-486 (Oral 
Azacitidine) in 
Combination With 
Pembrolizumab (MK-
3475) Versus 
Pembrolizumab Plus 
Placebo in Subjects With 
Previously Treated 
Locally Advanced or 
Metastatic Non-small 
Cell Lung Cancer 
Recruiting 
CC-486 
(Oral 
Azacitidine) 
Pembrolizumab 
(MK-3475)  
  
Carcinoma, Non-
Small-Cell Lung 
Last updated: 
December 23, 2015 
Last verified: 
December 2015 
NCT02395627 
First received: March 
17, 2015 
Reversing Hormone 
Therapy Resistance 
With Epigenetic-
immune Modification: 
Phase II Trial of 
Vorinostat, Tamoxifen 
and Pembrolizumab in 
Hormone Receptor 
Expressing Advanced 
Breast Cancer 
Recruiting Vorinostat Pembrolizumab 
Tamoxife
n 
Breast Neoplasms 
Last updated: 
September 29, 2015 
Last verified: 
September 2015 
NCT01834248 
First received: April 
12, 2013 
A Phase I Study of 
DEC205mAb-NY-ESO-1 
Fusion Protein (CDX-
1401) Given With 
Adjuvant PoIylCLC in 
Conjunction With 5-Aza-
2'Deoxycytidine 
(Decitabine) in Patients 
With MDS or Low Blast 
Count AML 
Active, not 
recruiting 
Decitabine 
DEC-205/NY-
ESO-1 Fusion 
Protein CDX-1401 
  
Acute Myeloid 
Leukemia 
Last updated: June 
30, 2015 
Alkylating Agent-
Related Acute 
Myeloid Leukemia 
Last verified: June 
2015 Poly ICLC 
Chronic 
Myelomonocytic 
Leukemia 
  
  
Myelodysplastic 
Syndrome 
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Refractory Anemia 
With Excess 
Blasts in 
Transformation 
NCT02518958 
First received: August 
4, 2015 
A Phase I, Open-Label, 
Multiple Ascending Dose 
Study to Assess the 
Safety and Tolerability of 
RRx-001 and Nivolumab 
in Subjects With 
Advanced Solid Tumors 
or Lymphomas For 
Which There Are No 
Currently Accepted Life-
Prolonging Therapies 
(PRIMETIME) 
Recruiting Azacitidine Nivolumab   
Malignant Solid 
Tumor 
Last updated: October 
29, 2015 
Lymphoma 
Last verified: August 
2015 
  
NCT01120834 
First received: April 
19, 2010 
Phase I/II Study of 5-
azacitidine in 
Combination With 
Vorinostat in Patients 
With Relapsed or 
Refractory DLBCL 
unknown Azacytidine vorinostat   Lymphoma 
Last updated: October 
27, 2010 
Last verified: October 
2010 
NCT01928576 
First received: August 
21, 2013 
A Randomized Phase II 
Study of Epigenetic 
Priming With Azacitidine 
and Entinostat or Oral 
Azacitidine Alone Prior 
to Nivolumab in Subjects 
With Recurrent 
Metastatic Non-Small 
Cell Lung Cancer. 
Recruiting 
Azacitidine 
Nivolumab 
  
Non-Small Lung 
Cancer 
Last updated: October 
13, 2015 
Entinostat   
Last verified: October 
2015 
    
NCT01038778 
First received: 
December 18, 2009 
Phase I/II Study of High 
Dose Interleukin 2, 
Aldesleukin, in 
Combination With the 
Histone Deacetylase 
Inhibitor Entinostat in 
Patients With Metastatic 
Recruiting Entinostat Aldesleukin   
Clear Cell Renal 
Cell Carcinoma 
Last updated: January 
15, 2016 
Metastatic Renal 
Cell Cancer 
Last verified: January 
2016 
Stage III Renal 
Cell Cancer 
  Stage IV Renal 
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Renal Cell Carcinoma Cell Cancer 
NCT02332889 
First received: 
October 20, 2014 
A Phase I/Pilot II Trial 
Combining Decitabine 
and Vaccine Therapy for 
Patients With Relapsed 
or Refractory Pediatric 
High Grade Gliomas, 
Medulloblastomas, and 
CNS PNETs 
Recruiting Decitabine 
Vaccine 
(autologous 
dendritic cells) 
  
  
Last updated: 
November 30, 2015 
  
Last verified: 
November 2015 
Hiltonol   
NCT01241162 
First received: 
November 15, 2010 
A Phase I Trial 
Combining Decitabine 
and Vaccine Therapy for 
Patients With Relapsed 
Neuroblastoma and 
Sarcoma. 
Recruiting Decitabine 
Autologous 
dendritic cell 
vaccine with 
adjuvant 
  
Neuroblastoma 
Last updated: 
December 2, 2015 
Ewings Sarcoma 
Last verified: 
November 2015 
Osteogenic 
Sarcoma 
  Rhabdomyosarco
ma 
  Synovial Sarcoma 
NCT01966289 
First received: 
October 10, 2013 
A Pilot Study of SGI-110 
in Combination With an 
Allogeneic Colon Cancer 
Cell Vaccine (GVAX) 
and Cyclophosphamide 
(CY) in Metastatic 
Colorectal Cancer 
(mCRC) as Maintenance 
Therapy 
Recruiting SGI-110 GVAX CY 
Metastatic 
Colorectal Cancer 
Last updated: 
December 8, 2015 
Last verified: 
December 2015 
NCT02512172 
First received: July 2, 
2015 
A Pilot Study of 
Using Epigenetic Modula
tors to Enhance 
Response to MK-3475 in 
Microsatellite Stable 
Advanced 
Colorectal Cancer 
Recruiting 
Oral CC - 
486 
Romidepsin 
  Colorectal Cancer 
Last updated: July 27, 
2015 
MK - 3475 
Last verified: July 
2015   
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Table 1: Ongoing clinical trials assessing combinations of epigenetic and immunomodulatory therapies, found at https://clinicaltrials.gov/ as of January 
2016. 
